Loading…
This event has ended. Visit the official site or create your own event on Sched.
Learn the latest cancer care information to benefit your patients and earn up to 30 CNE contact hours! Register now at congress.ons.org.
View analytic
Saturday, April 30 • 12:15pm - 1:45pm
REVLIMID® (lenalidomide) Treatment For Patients With Deletion 5q Myelodysplastic Syndromes: A Nurse’s Perspective*

Sign up or log in to save this to your schedule and see who's attending!

Please join us for a Celgene presentation of REVLIMID® in the treatment of del(5q) myelodysplastic syndromes (MDS). Sandra Kurtin, RN, MS, AOCN, ANP-C, from the University of Arizona Cancer Center will walk you through an overview of MDS, discuss considerations for the treatment of patients with MDS, present patient cases, and review the use of REVLIMID and important safety information. We are looking forward to your attendance. 

This program is sponsored by Celgene Corporation